Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa
Abstract Although viral suppression is attained for most adults living with diagnosed HIV in East, Central, Southern and West Africa (ECSWA), challenges remain with sustained adherence to daily oral pill taking for some in the population. Here, we evaluate the potential effectiveness and cost-effect...
Saved in:
| Main Authors: | Andrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, Kenly Sikwese, Cissy Kityo, Charles Flexner, Marco Vitoria, Nathan Ford, Meg Doherty, Zack Panos, David Ripin, Matthew Hickey, Diane Havlir, Monica Gandhi, Michael Reid, Paul Revill |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60752-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir
by: Derek Hansen, et al.
Published: (2025-05-01) -
Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably
by: Valeria D. Cantos, et al.
Published: (2025-07-01) -
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
by: Rosie Mngqibisa, et al.
Published: (2025-07-01) -
Development and Validation of Stability Indicating RP-HPLC Method for the Simultaneous Determination of Cabotegravir and Rilpivirine in Bulk and Injection Dosage Form
by: A Suneetha, et al.
Published: (2022-12-01) -
Genetic Diversity in the Capsid Protein-Coding Region of HIV-1 Circulating in Benguela, Angola: Implications for Primary Resistance to the Novel Capsid Inhibitor Lenacapavir
by: Gonçalo Queirós, et al.
Published: (2025-05-01)